Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/9832

Toxic equivalency factor evaluation (Dioxin mixture): Target Organs and Levels of Evidence for TR-526

Toxicology and Carcinogenesis Studies of a Mixture of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) (CASRN 1746-01-6), 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (CASRN 57117-31-4), and 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) (CASRN 57465-28-8) in Female Harlan Sprague-Dawley Rats (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
TEF evaluation (Dioxin mixture)
TEFDIOXINMIX
02/17/2004The main sources of TCDD and PeCDF releases into the environment are from metal smelting, refining, & processing; combustion & incineration sources; chemical manufacturing & processing; biological & photochemical processes; and existing reservior sources that reflect past releases. Used as dielectric insulating fluids in transformers & capacitors and used in hydraulic fluids, plastics, & paints.Gavage
FEMALE RATS ONLY: 0, (TCDD) 3.3, 7.3, 15.2, OR 33 NG/KG; (PeCDF) 6.6, 14.5, 30.4, OR 66 NG/KG; (PCB 126) 33.3, 73.3, 153, OR 333 NG/KG; 100/DOSE
Battelle Columbus Laboratory

Levels of Evidence

Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 0/53 1/53 1/53 1/53 11/51 OR CHOLANGIOCARCINOMA 0/53 0/53 2/53 7/53 9/51
  • Lung: CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/53 2/53 20/53
May Have Been Related
  • Pancreas Acinar Cell: ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51
Non-Neoplastic Lesions
  • LIVER: HEPATOCYTE HYPERTROPHY; MULTINUCLEATED HEPATOCYTE; PIGMENTATION; INFLAMMATION; DIFFUSE FATTY CHANGE; BILE DUCT HYPERPLASIA; OVAL CELL HYPERPLASIA; NODULAR HYPERPLASIA; EOSINOPHILIC FOCUS; CHOLANGIOFIBROSIS; BILE DUCT CYST; NECROSIS; PORTAL FIBROSIS; MIXED CELL FOCUS; TOXIC HEPATOPATHY
  • LUNG: ALVEOLAR EPITHELIUM, METAPLASIA, BRONCHIOLAR; SQUAMOUS METAPLASIA
  • PANCREAS: ARTERIAL CHRONIC ACTIVE INFLAMMATION; ACINAR CYTOPLASMIC VACUOLIZATION; ACINAR ATROPHY; CHRONIC ACTIVE INFLAMMATION; DUCT DILATATION
  • ADRENAL CORTEX: HYPERPLASIA; CYSTIC DEGENERATION; ATROPHY; CYTOPLASMIC VACUOLIZATION
  • ORAL MUCOSA: GINGIVAL SQUAMOUS HYPERPLASIA
  • UTERUS: SQUAMOUS METAPLASIA
  • THYMUS: ATROPHY; SEVERITY OF ATROPHY
  • OVARY: CHRONIC ACTIVE INFLAMMATION
  • KIDNEY: NEPHROPATHY; SEVERITY OF NEPHROPATHY
  • HEART: CARDIOMYOPATHY
  • BONE MARROW: HYPERPLASIA
  • URINARY BLADDER: TRANSITIONAL EPITHELIAL HYPERPLASIA
  • MESENTERY: ARTERIAL CHRONIC ACTIVE INFLAMMATION
  • THYROID GLAND: FOLLICULAR CELL HYPERTROPHY